Jean‐Paul Pirnay

11.0k total citations · 3 hit papers
133 papers, 6.9k citations indexed

About

Jean‐Paul Pirnay is a scholar working on Ecology, Molecular Biology and Microbiology. According to data from OpenAlex, Jean‐Paul Pirnay has authored 133 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Ecology, 54 papers in Molecular Biology and 38 papers in Microbiology. Recurrent topics in Jean‐Paul Pirnay's work include Bacteriophages and microbial interactions (85 papers), Microbial infections and disease research (31 papers) and Antibiotic Resistance in Bacteria (23 papers). Jean‐Paul Pirnay is often cited by papers focused on Bacteriophages and microbial interactions (85 papers), Microbial infections and disease research (31 papers) and Antibiotic Resistance in Bacteria (23 papers). Jean‐Paul Pirnay collaborates with scholars based in Belgium, United Kingdom and United States. Jean‐Paul Pirnay's co-authors include Daniël De Vos, Gilbert Verbeken, Rob Lavigne, Martin Zizi, Pierre Cornélis, Serge Jennes, Mario Vaneechoutte, Maia Merabishvili, Maya Merabishvili and A. Vanderkelen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and PLoS ONE.

In The Last Decade

Jean‐Paul Pirnay

132 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial

2018 595 citations Serge Jennes, Jean‐Paul Pirnay et al. profile →
Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae

2022 194 citations Jeroen Wagemans, Ніна Чанішвілі et al. profile →
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches

2025 27 citations Sabrina I. Green, Rob Lavigne et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean‐Paul Pirnay Belgium	47	4.7k	2.7k	2.0k	1.4k	1.1k	133	6.9k
Daniël De Vos Belgium	39	3.1k 0.7×	2.1k 0.8×	1.3k 0.7×	1.1k 0.8×	907 0.8×	84	5.1k
Elizabeth Kutter United States	46	5.6k 1.2×	2.9k 1.1×	1.8k 0.9×	509 0.4×	978 0.9×	77	6.8k
Stephen T. Abedon United States	50	7.8k 1.7×	3.0k 1.1×	2.8k 1.4×	695 0.5×	1.8k 1.7×	96	8.9k
Beata Weber‐Dąbrowska Poland	44	4.8k 1.0×	1.8k 0.7×	1.9k 1.0×	478 0.3×	793 0.7×	117	5.6k
Benjamin K. Chan United States	22	3.1k 0.7×	1.3k 0.5×	1.2k 0.6×	620 0.4×	618 0.6×	44	3.8k
Jeremy J. Barr Australia	27	3.4k 0.7×	1.8k 0.7×	902 0.5×	433 0.3×	668 0.6×	68	4.6k
Andrew M. Kropinski Canada	58	8.4k 1.8×	5.8k 2.2×	2.6k 1.4×	1.1k 0.8×	2.2k 2.0×	255	12.4k
Daniel Nelson United States	35	2.9k 0.6×	2.3k 0.9×	1.0k 0.5×	349 0.2×	503 0.5×	102	5.1k
José R. Penadés Spain	55	3.4k 0.7×	6.4k 2.4×	1.6k 0.8×	789 0.6×	629 0.6×	126	10.0k
Rob Lavigne Belgium	70	12.0k 2.6×	7.3k 2.8×	4.1k 2.1×	1.3k 1.0×	2.9k 2.6×	349	15.3k

Countries citing papers authored by Jean‐Paul Pirnay

Since Specialization

Citations

This map shows the geographic impact of Jean‐Paul Pirnay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Paul Pirnay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Paul Pirnay more than expected).

Fields of papers citing papers by Jean‐Paul Pirnay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Paul Pirnay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Paul Pirnay. The network helps show where Jean‐Paul Pirnay may publish in the future.

Co-authorship network of co-authors of Jean‐Paul Pirnay

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Paul Pirnay. A scholar is included among the top collaborators of Jean‐Paul Pirnay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Paul Pirnay. Jean‐Paul Pirnay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Castledine, Meaghan, Brieuc Van Nieuwenhuyse, Sarah Djebara, et al.. (2025). Predicting clinical phage therapy outcomes in vitro : results using mixed versus single isolates from an MRSA case study. Journal of Applied Microbiology. 136(6).

Vos, Daniël De, et al.. (2025). Exploring Phage-Antibiotic Synergies in The Context of Biofilm-related Infectious Diseases. International Journal of Infectious Diseases. 152. 107590–107590. 1 indexed citations

Midtlyng, Paul J., et al.. (2025). Bacteriophage-based veterinary products: aligning regulatory framework and development challenges for market integration. Biologicals. 91. 101847–101847. 1 indexed citations

Wang, Zhifen, Steven De Soir, Maya Merabishvili, et al.. (2024). Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. International Journal of Antimicrobial Agents. 64(3). 107276–107276. 3 indexed citations

Turner, Paul E., Joana Azeredo, Ed T. Buurman, et al.. (2024). Addressing the Research and Development Gaps in Modern Phage Therapy. PubMed. 5(1). 30–39. 11 indexed citations

Blasco, Lucía, Inmaculada López-Hernández, Javier Pérez-Florido, et al.. (2023). Case report: Analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection. Frontiers in Medicine. 10. 1199657–1199657. 34 indexed citations

Uyttebroek, Saartje, Willem‐Jan Metsemakers, Yves Debaveye, et al.. (2023). Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections. Microbiology Spectrum. 11(6). e0290723–e0290723. 11 indexed citations

McCallin, Shawna, Zuzanna Drulis‐Kawa, Tristan Ferry, Jean‐Paul Pirnay, & Ran Nir‐Paz. (2023). Phages and phage-borne enzymes as new antibacterial agents. Clinical Microbiology and Infection. 31(6). 910–921. 13 indexed citations

Rācenis, Kārlis, Sarah Djebara, Maya Merabishvili, et al.. (2023). Successful Bacteriophage-Antibiotic Combination Therapy against Multidrug-Resistant Pseudomonas aeruginosa Left Ventricular Assist Device Driveline Infection. Viruses. 15(5). 1210–1210. 20 indexed citations

10.

Bleriot, Inés, Olga Pacios, Lucía Blasco, et al.. (2023). Improving phage therapy by evasion of phage resistance mechanisms. JAC-Antimicrobial Resistance. 6(1). dlae017–dlae017. 33 indexed citations

11.

Young, Matthew J., et al.. (2023). Phage Therapy for Diabetic Foot Infection: A Case Series. Clinical Therapeutics. 45(8). 797–801. 30 indexed citations

12.

Pirnay, Jean‐Paul & Gilbert Verbeken. (2023). Magistral Phage Preparations: Is This the Model for Everyone?. Clinical Infectious Diseases. 77(Supplement_5). S360–S369. 25 indexed citations

13.

Merabishvili, Maya, Rob Lavigne, Jeroen Wagemans, et al.. (2022). Isolation and Characterization of Lytic Pseudomonas aeruginosa Bacteriophages Isolated from Sewage Samples from Tunisia. Viruses. 14(11). 2339–2339. 16 indexed citations

14.

Castledine, Meaghan, Daniel Padfield, Pawel Sierocinski, et al.. (2022). Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 53 indexed citations

15.

Lebeaux, David, Maia Merabishvili, Éric Caudron, et al.. (2021). A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses. 13(1). 60–60. 88 indexed citations

16.

Mestdagh, Pieter, Michel Gillard, Jean‐Paul Pirnay, et al.. (2021). Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load. Journal of Molecular Diagnostics. 23(10). 1249–1258. 6 indexed citations

17.

Merabishvili, Maya, Jean‐Paul Pirnay, Daniël De Vos, et al.. (2019). Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). Scientific Reports. 9(1). 13893–13893. 24 indexed citations

18.

Thrane, Sandra Wingaard, Véronique L. Taylor, Luca Freschi, et al.. (2015). The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters. mBio. 6(5). 46 indexed citations

19.

Verbeken, Gilbert, Isabelle Huys, Jean‐Paul Pirnay, et al.. (2014). Taking Bacteriophage Therapy Seriously: A Moral Argument. BioMed Research International. 2014. 1–8. 32 indexed citations

20.

Merabishvili, Maia, Daniël De Vos, Gilbert Verbeken, et al.. (2012). Selection and Characterization of a Candidate Therapeutic Bacteriophage That Lyses the Escherichia coli O104:H4 Strain from the 2011 Outbreak in Germany. PLoS ONE. 7(12). e52709–e52709. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact